NYSE:GKOS - Glaukos Stock Price, News, & Analysis

$74.70
-0.95 (-1.26 %)
(As of 06/24/2019 01:14 PM ET)
Today's Range
$74.65
Now: $74.70
$76.36
50-Day Range
$63.81
MA: $69.58
$78.23
52-Week Range
$36.89
Now: $74.70
$83.14
Volume7,496 shs
Average Volume358,387 shs
Market Capitalization$2.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone949-367-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.28 million
Book Value$4.98 per share

Profitability

Net Income$-12,950,000.00

Miscellaneous

Employees437
Market Cap$2.72 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.

Glaukos (NYSE:GKOS) Frequently Asked Questions

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) posted its earnings results on Wednesday, May, 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.08. The medical instruments supplier had revenue of $54.03 million for the quarter, compared to the consensus estimate of $50.13 million. Glaukos had a negative return on equity of 6.90% and a negative net margin of 5.93%. View Glaukos' Earnings History.

When is Glaukos' next earnings date?

Glaukos is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Glaukos.

What price target have analysts set for GKOS?

8 Wall Street analysts have issued 1-year target prices for Glaukos' shares. Their forecasts range from $57.00 to $80.00. On average, they anticipate Glaukos' stock price to reach $71.3775 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View Analyst Price Targets for Glaukos.

What is the consensus analysts' recommendation for Glaukos?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos.

What are Wall Street analysts saying about Glaukos stock?

Here are some recent quotes from research analysts about Glaukos stock:
  • 1. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019)
  • 2. According to Zacks Investment Research, "Glaukos outperformed the industry in a year’s time. Moreover, the company issued guidance for 2019. In the past year, Glaukos made significant progress on the regulatory front and commenced the U.S. commercial launch of iStent Inject. Also, it initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Nonetheless, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning. The stock looks a bit expensive at the moment." (4/30/2019)

Has Glaukos been receiving favorable news coverage?

Press coverage about GKOS stock has trended very negative on Monday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Glaukos earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future. View News Stories for Glaukos.

Who are some of Glaukos' key competitors?

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include Alibaba Group (BABA), PTC Therapeutics (PTCT), Twilio (TWLO), Paypal (PYPL), Splunk (SPLK), Boeing (BA), EXACT Sciences (EXAS), NVIDIA (NVDA), Canopy Growth (CGC) and DexCom (DXCM).

Who are Glaukos' key executives?

Glaukos' management team includes the folowing people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)
  • Mr. Richard L. Harrison, Advisor (Age 62)
  • Dr. Mory Gharib Ph.D., Co-Founder

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (6.77%), FMR LLC (4.89%), Baillie Gifford & Co. (4.83%), Gilder Gagnon Howe & Co. LLC (3.42%), Janus Henderson Group PLC (2.95%) and Artisan Partners Limited Partnership (2.30%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.

Which institutional investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Jennison Associates LLC, Peregrine Capital Management LLC, SG Americas Securities LLC, Federated Investors Inc. PA, First Trust Advisors LP and First Trust Advisors LP. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View Insider Buying and Selling for Glaukos.

Which institutional investors are buying Glaukos stock?

GKOS stock was acquired by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Granite Investment Partners LLC, Timpani Capital Management LLC, Baillie Gifford & Co., Laurion Capital Management LP, Victory Capital Management Inc., Picton Mahoney Asset Management and Advisor Group Inc.. View Insider Buying and Selling for Glaukos.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $74.72.

How big of a company is Glaukos?

Glaukos has a market capitalization of $2.72 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos.

What is Glaukos' official website?

The official website for Glaukos is http://www.glaukos.com/.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]


MarketBeat Community Rating for Glaukos (NYSE GKOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  318 (Thanks for Voting!)
Underperform Votes:  227 (Thanks for Voting!)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel